News September 7 2017

TiGenix has obtained a licence for commercial production at its Spanish facility

TiGenix has obtained a licence for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid, Spain, following an inspection by the Spanish Medicines Agency (AEMPS). This licence will provide the company with production capacity for the potential European commercial roll out of Cx601, which is an investigational stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn’s disease. Additionally, this expanded facility offers the company the opportunity to manufacture other pipeline products. “We are very pleased with this approval for our expanded facility, which confirms our state-of-the-art GMP manufacturing capabilities in the stem cell field,” said Wilfried Dalemans, Chief Technical Officer at TiGenix. “We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialization of Cx601 in Europe and in the further development of our pipeline.” The company has submitted a marketing authorisation (MA) application for Cx601 to the European Medicines Agency (EMA) and a decision is anticipated this year. Should it be approved it will enable marketing of the product in all 28 EU member states as well as Norway, Iceland and Lichenstein. Cx601 has been licensed to Takeda for exclusive development and commercialization outside of the US.

News August 17 2017

Kiadis Pharma obtains up to €15m debt financing from Kreos Capital

Kiadis Pharma N.V. a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has obtained a debt facility of up to €15 million from Kreos Capital. The loan consists of two tranches, with the first tranche of €10 million immediately drawn down and a second tranche of €5 million upon the company raising €20 million in additional funds. Kiadis Pharma will use the loan to advance the development of the Company's ATIR products, for general corporate purposes and to repay the remaining €5.3 million of existing Dutch Government Loans. Arthur Lahr, CEO of Kiadis Pharma, commented: "We are pleased with this non-dilutive debt funding from Kreos Capital, Europe's largest provider of debt-financing solutions to high-growth companies. The loan allows us to refinance an existing loan with improved terms and extends our cash runway, as we progress towards potentially obtaining marketing approval for ATIR101™ in the European Union in the second half of 2018." Maurizio PetitBon, General Partner of Kreos Capital, commented: "We are pleased to be supporting Kiadis Pharma, a company that is advancing the field of allogeneic hematopoietic stem cell transplantations and is improving the outcomes of patients suffering from blood cancers and inherited blood disorders. The flexible funding provided by Kreos will provide a strong foundation for Kiadis to advance the development of ATIR101™." About ATIR101™ For patients suffering from blood cancers and inherited blood disorders, an allogeneic hematopoietic stem cell transplantation (HSCT) can offer a cure, yet it has considerable risks. During an HSCT treatment, the patient's diseased blood and immune system are destroyed and subsequently replaced by a healthy system from a donor. The key challenge with HSCT is that mature lymphocytes from the donor are required to provide immediate protection against infections and relapse, but may attack patient tissue, causing life threatening Graft-versus-Host-Disease (GVHD). ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) provides for a single dose donor lymphocyte infusion, with functional, mature immune cells from a haploidentical family member, given as an adjunctive to a haploidentical HSCT. The lymphocytes in ATIR101™ are very potent in fighting infections and remaining tumor cells, yet do so with minimal risk of causing severe GVHD. To provide protection to patients without attacking patient tissue, ATIR101™ is manufactured by depleting patient specific alloreactive lymphocytes ex vivo from donor material. ATIR101™ offers a strong improvement in relapse rates and GVHD over literature for other HSCT protocols, such as the Post Transplant Cyclophosphamide (PTCy) or 'Baltimore' protocol. About Kiadis Pharma Kiadis Pharma is focused on cell-based immunotherapy products, as an adjunctive to a haploidentical hematopoietic stem cell transplantation (HSCT), for the treatment of blood cancers and inherited blood disorders. The Company's productcandidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients. Based on the positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the European Union as an adjunctive treatment in HSCT for malignant disease. In addition, Kiadis Pharma has received regulatory approval in various countries to start dosing patients in a Phase III trial with ATIR101™ that will be performed across Europe and North America. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe. The Company's second product candidate, ATIR201™, will address beta thalassemia, an inherited blood disorder. Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA. The Company's shares are listed on Euronext Amsterdam and Euronext Brussels. For more information visit About Kreos Kreos Capital has been prominent for 19 years as the leading provider of growth debt financing in Europe and Israel to high-growth companies with revenues up to USD 200 million. As the pioneer growth debt provider across Europe and Israel, Kreos has completed over 450 transactions and committed USD 1.9 billion in 15 different countries. Kreos is dedicated to supporting management teams and their equity investors with flexible loan structures for all stages of a growth company's development, and to addressing the needs for growth capital, working capital, acquisition financings, lower mid-market buy-outs, roll-up strategies, bank re-financings as well as pre- and post-IPO financings. Kreos's most recent fund, Kreos V, was launched in January 2016 with USD 440 million committed from top-tier institutional investors for investment in our portfolio companies.

News August 16 2017

Retail deposits platform Savedo acquired by fellow fintech Deposit Solutions

Germany-based Deposit Solutions has acquired fellow fintech Savedo. With the acquisition of Savedo, Deposit Solutions gains 18,000+ clients, 13 partner banks and new regions – thus “further expanding its B2C capabilities”. Founded in 2011, Deposit Solutions provides the Open Banking platform – for instant-access and fixed-term savings across Europe. The fintech says 30 banks in ten European countries are connected to Open Banking, including Deutsche Bank and Fidelity Investments’ German subsidiary FBB. It employs 120 people. Deposit Solutions also operates a B2C offering, Zinspilot. It was launched in 2015 for “savers whose home banks haven’t implemented Open Banking yet”, the company says. It has over 60,000 retail savers using Zinspilot today, and has “mediated” over €2 billion in deposits since its launch. Savedo, too, provides a platform for retail deposits. It is available in three languages and Deposit Solutions hopes it will boost the firm’s international roll-out. Christian Tiessen, Savedo’s CEO, will take on responsibility for the international B2C expansion of Deposit Solutions. Savedo will continue to operate out of its Berlin location. Deposit Solutions’ HQ is in Hamburg, and it has offices in Zurich and London. The company has received €25 million in venture capital funding to date, including from Greycroft Partners, FinLab,, Valar Ventures and Peter Thiel). When it held its last investment round in July 2016, it was valued at €110 million.

News August 15 2017

CellSavers Rebrands as Puls and Raises $25m to Expand its Instant Services for Smart Devices

CellSavers, the instant services company for smart devices, has rebranded as Puls and raised $25 million in a new round of funding. The funding round is led by Red Dot Capital Partners -- a Temasek Holdings backed growth fund -- with support from new investors Samsung NEXT, Maverick Ventures and Kreos Capital along with participation from existing investors Sequoia Capital and Carmel Ventures. With $43 million raised to date, the new funding will empower Puls to widen its current offering of rapid-response, in-home digital services beyond cell phone and tablet repair to span flat screens, security cameras, voice-control and home automation products from any smart device manufacturer. The company is expanding its offering to cover the full lifecycle of a digital device, encompassing in-home demonstration, installation, setup, integration, support, repair and trade-in. The funding will also be used to expand into new U.S. markets. Puls has developed a powerful technology platform, using proprietary algorithms to intelligently match consumers in need of smart device repairs or installation, with the right qualified technician in their area to arrive on time and complete each task on the spot. With a network of more than 1,000 vetted technicians in more than 40 markets, Puls schedules appointments within 60 minutes to almost any covered location, and offers a lifetime guarantee on all repairs. By focusing on the end-to-end customer experience, the company provides a single point of contact for consumers and technicians, ensuring unmatched convenience and customer satisfaction. "We know how frustrating it is when your digital devices stop working, and at Puls we're here whenever you need us, to get you up and running in no time, to keep your digital heart beating at all times," said CEO and co-founder, Eyal Ronen. "We're on a mission, and with incredible team members, partners and advisors, we're perfectly positioned to tackle one of the biggest gaps between consumers and the proliferating digital devices at the center of our lives. While tech products are becoming smarter every year, it's getting harder to configure or fix them. We've cracked the code on how to deliver same-day service that's seamless to the customer, rewarding for the technician, and scalable as a business. We're delighted to unveil the new brand for our vision beyond 60-minute cell phone repair, where we've served over 100,000 customers. Puls is the trusted brand you can count on for all the ups and downs of digital life." "The increasing consumer reliance on digital device connectivity, whether at home or on the move, is driving a growing need for a trusted, on-demand setup and repair service for digital products. Puls offers customers across the U.S. a convenient, professional and reliable service that will show up wherever needed and within minutes of request, and customers are just raving about their service," said Yaniv Stern, Managing Partner at Red Dot Capital Partners. "We are thrilled to lead this financing round and are excited to support Puls as it enters an accelerated growth phase." Since opening in 2015, the company has grown significantly, struck strategic partnerships with industry leading device manufacturers, such as Google, and has proven its service-first model with thousands of 5-star customer reviews on Facebook and Yelp. About Puls Founded in 2015 by Itai Hirsch and Eyal Ronen, Puls (formerly CellSavers) connects consumers with highly skilled technicians to install, support or repair their smart technology devices anytime, anywhere. Providing services in more than 40 markets, Puls leverages a proprietary technology platform to match customers with the right skilled technician, managing the process from start to finish, with most repairs addressed within 60 minutes. With thousands of 5-star reviews on Facebook and Yelp, Puls goes the extra mile for its customers to ensure exceptional service and guaranteed results. Headquartered in San Francisco with offices in San Diego and Tel Aviv, Puls has raised $43 million in financing with backing from Sequoia Capital, Carmel Ventures, Red Dot Capital (Temasek Holdings), Samsung NEXT, Maverick Ventures and Kreos Capital. Learn more at

News June 21 2017

NASDAQ Welcomes Bonesupport to the Main Market

Nasdaq (Nasdaq: NDAQ) announced that Bonesupport Holding AB (short name: BONEX), a small cap company within the health care sector, has started trading of its shares on the main market of Nasdaq Stockholm. Bonesupport is the 63rd company to list at Nasdaq’s Nordic markets* in 2017. Bonesupport is a Swedish commercial stage orthobiologics company aiming to improve the lives of patients suffering from bone disorders. The company develops and commercializes injectable bioceramic bone graft substitutes to treat bone voids, based on its novel, proprietary Cerament technology platform. Bonesupport is headquartered at the Ideon Science Park in Lund, Sweden, with additional sales offices in Germany and the US. For more information, please visit “We are pleased to have completed our IPO on the Nasdaq Stockholm main market and that our shares have started trading today,” said Richard Davies, CEO of Bonesupport. “Our listing is a key step in supporting Bonesupport’s growth strategy. Our IPO has provided us with the funds to drive our sales in both the US and Europe, to generate additional clinical data to enhance the competitive positioning of our products, to complete the Fortify study, which is key to gaining US approval for Cerament G, and to invest in our pipeline. This strategy will allow us to deliver our 2020 financial targets and to generate significant value for shareholders.” “We welcome Bonesupport to the Nasdaq Stockholm main market,” said Adam Kostyál, SVP and Head of European listings at Nasdaq. “We continue to see a strong inflow of health care sector companies leveraging the public markets as a platform for future growth, and Bonesupport will make an exciting addition to that list.”